FDA Approves First Gene Therapy for Hemophilia B FDA Approves First Gene Therapy for Hemophilia B

Etranacogene dezaparvovec is the first gene therapy option for adults with hemophilia B who use factor IX prophylaxis and have repeated, spontaneous bleeding episodes. This one-time gene therapy has a list price of $3.5 million.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news